News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Subscribe To Our Newsletter & Stay Updated
